Mesothelioma Treatment
Mesothelioma Cancer
- Causes of Mesothelioma
- Mesothelioma Symptoms
- Mesothelioma Diagnosis
- Mesothelioma Stages
- Mesothelioma Treatment
- Innovative Mesothelioma Treatments
- Managing Mesothelioma Pain
- Nutrition Information for Mesothelioma Patients
- Specialized Mesothelioma Care
- Mesothelioma Risks
- Mesothelioma Support Groups
- Find a Mesothelioma Attorney
- Mesothelioma News
Mesothelioma Directory
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
Get Help Today
Looking for help or additional information? Contact us today.| Conditions: | Malignant Epithelial Mesothelioma|Adenocarcinoma of the Pancreas|Carcinoma, Non-Small-Cell Lung|Adenocarcinoma of the Ovaries |
| Start Date: | December 1, 2007 |
| Phase: | Phase I |
| Status: | Terminated |
| NCT ID: | NCT00585845 |
| Study Type: | Interventional |
| Intervention: | Biological: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin |
| Study Design: | Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | Anza Therapeutics, Inc. |
| Ages: | Adult|Senior |
| Enrollment: | 17 |
| Funded By: | Industry |
| First Received: | December 22, 2007 |
| End Date: | February 1, 2009 |
| Last Updated: | February 19, 2009 |
| Last Verified: | February 1, 2009 |